Novartis AG

“Novartis is a structurally sound, best-in-class pharma compounder with a genuine RLT platform moat, fortress balance sheet, and 25+ years of dividend growth — but at 15x forward earnings and CHF 115, the price already reflects competent execution, leaving limited margin of safety against the very real Cosentyx patent cliff and pipeline binary risk; the right action is to track for a 15–20% pullback to CHF 88–98 before initiating or adding, while existing holders have no compelling reason to sell a cash-generative franchise returning 5–6% annually through dividends and buybacks.”